Adicet Bio Q2 net loss $29.9M; expands ADI-001 into three more autoimmune indications

Adicet Bio, Inc.

2024-Q2 EPS reported -$0.68

Net loss $29.9M ($0.33/share) vs $32.4M ($0.75) in Q2 2023; cash $224.1M, sufficient into H2 2026.
FDA cleared IND for ADI-001 in SLE, SSc, AAV; Fast Track for LN; enrollment starts Q3 2024 with data H1 2025.
FDA cleared IND for ADI-270 in RCC with Fast Track Designation; Phase 1 to start Q4 2024, data H1 2025.
R&D expenses $25.9M, down from $28.4M; G&A $6.9M, up from $6.5M.
MCL enrollment ongoing in ADI-001 Phase 1 GLEAN study; clinical update Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.